Prednisolone sodium phosphate is under clinical development by Enceladus Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Prednisolone sodium phosphate’s likelihood of approval (LoA) and phase transition for Graves’ Ophthalmopathy took place on 01 Mar 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Prednisolone sodium phosphate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Prednisolone sodium phosphate overview

PEG-liposomal prednisolone sodium phosphate (Nanocort) is under development for the treatment of Graves' orbitopathy, ulcerative colitis and for prevention of kidney transplant rejection. The drug candidate is administered as intravenous infusion. It targets glucocorticoid receptor (GR). Nanocort is pegylated formulation that is composed of corticosteroids enclosed in carefully designed small lipid vesicles (liposomes) which selectively accumulate in inflamed tissues and in tumors. It was under development for the treatment of relapsing-remitting multiple sclerosis, rheumatoid arthritis and arteriovenous fistula.

Enceladus Pharmaceuticals overview

Enceladus Pharmaceuticals (Enceladus) is a developer of liposomal formulations. The company offers nanocort, a novel pharmaceutical drug composed of corticosteroids enclosed in small lipid vesicles that after intravenous injection selectively accumulate in inflamed tissues and in tumors. Its other products comprise oncocort, a liposomal dexamethasone for the treatment of prostate carcinoma and metastasized multiple myeloma; and innovicort for severe skin, eye, and mucosal tissue inflammation diseases. The company conducts preclinical studies that offer silencing inflammatory processes in and around tumors. It operates in the field of autoimmune diseases, inflammation, and cancer that are chronic, progressive, and debilitating. Enceladus is headquartered in Naarden, the Netherlands.

Quick View Prednisolone sodium phosphate LOA Data

Report Segments
  • Innovator
Drug Name
  • Prednisolone sodium phosphate
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Gastrointestinal
  • Immunology
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.